Response by CTCL subtype and stage for all patients (N = 54)
| Best response and response rate . | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CTCL subtype (per investigator) . | Stage . | 15 mg/m2, 3/4 wk % (n/N) . | Best response . | 15 mg/m2 or more, 3/4 wk % (n/N) . | Best response . | < 15 mg/m2, 3/4 wk % (n/N) . | Best response . | Overall, % (n/N) . | Best response . |
| Mycosis fungoides | IB | 60 (3/5) | 3 PR | 63 (5/8) | 5 PR | 0 (0/2) | — | 50 (5/10) | 5 PR |
| IIA | 0 (0/2) | — | 0 (0/2) | — | — | — | 0 (0/2) | — | |
| IIB | 67 (4/6) | 4 PR | 67 (8/12) | 8 PR | 20 (1/5) | 1 CR | 53 (9/17) | 1 CR; 8 PR | |
| III | 50 (1/2) | 1 PR | 50 (1/2) | 1 PR | — | — | 50 (1/2) | 1 PR | |
| IVA | 60 (3/5) | 3 PR | 60 (3/5) | 3 PR | 0 (0/1) | — | 50 (3/6) | 3 PR | |
| IVB | 0 (0/1) | — | 0 (0/1) | — | — | — | 0 (0/1) | — | |
| Sézary syndrome | IIB* | 50 (1/2) | 1 PR | 50 (1/2) | 1 PR | — | — | 50 (1/2) | 1 PR |
| III | 33 (1/3) | 1 CRu | 25 (1/4) | 1 CRu | — | — | 25 (1/4) | 1 CRu | |
| IVA | 0 (0/2) | — | 0 (0/2) | — | 0 (0/5) | — | 0 (0/7) | — | |
| IVB | 0 (0/1) | — | 50 (1/2) | 1 PR | — | — | 50 (1/2) | 1 PR | |
| Primary cutaneous anaplastic large cell lymphoma | IIB | — | — | 100 (1/1) | — | — | — | 100 (1/1) | 1 CR |
| All patients | 45 (13/29) | 51 (21/41) | 8 (1/13) | 41 (22/54) | |||||
| (95% CI: 26.4-64.3) | (95% CI: 35.1-67.1) | (95% CI: 0.2-36.0) | (95% CI: 27.6-55.0) | ||||||
| Best response and response rate . | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CTCL subtype (per investigator) . | Stage . | 15 mg/m2, 3/4 wk % (n/N) . | Best response . | 15 mg/m2 or more, 3/4 wk % (n/N) . | Best response . | < 15 mg/m2, 3/4 wk % (n/N) . | Best response . | Overall, % (n/N) . | Best response . |
| Mycosis fungoides | IB | 60 (3/5) | 3 PR | 63 (5/8) | 5 PR | 0 (0/2) | — | 50 (5/10) | 5 PR |
| IIA | 0 (0/2) | — | 0 (0/2) | — | — | — | 0 (0/2) | — | |
| IIB | 67 (4/6) | 4 PR | 67 (8/12) | 8 PR | 20 (1/5) | 1 CR | 53 (9/17) | 1 CR; 8 PR | |
| III | 50 (1/2) | 1 PR | 50 (1/2) | 1 PR | — | — | 50 (1/2) | 1 PR | |
| IVA | 60 (3/5) | 3 PR | 60 (3/5) | 3 PR | 0 (0/1) | — | 50 (3/6) | 3 PR | |
| IVB | 0 (0/1) | — | 0 (0/1) | — | — | — | 0 (0/1) | — | |
| Sézary syndrome | IIB* | 50 (1/2) | 1 PR | 50 (1/2) | 1 PR | — | — | 50 (1/2) | 1 PR |
| III | 33 (1/3) | 1 CRu | 25 (1/4) | 1 CRu | — | — | 25 (1/4) | 1 CRu | |
| IVA | 0 (0/2) | — | 0 (0/2) | — | 0 (0/5) | — | 0 (0/7) | — | |
| IVB | 0 (0/1) | — | 50 (1/2) | 1 PR | — | — | 50 (1/2) | 1 PR | |
| Primary cutaneous anaplastic large cell lymphoma | IIB | — | — | 100 (1/1) | — | — | — | 100 (1/1) | 1 CR |
| All patients | 45 (13/29) | 51 (21/41) | 8 (1/13) | 41 (22/54) | |||||
| (95% CI: 26.4-64.3) | (95% CI: 35.1-67.1) | (95% CI: 0.2-36.0) | (95% CI: 27.6-55.0) | ||||||
3/4 indicates 3 of 4 weeks; CTCL, cutaneous T-cell lymphoma; CI, confidence interval; CR, complete response; CRu, CR unconfirmed; TNM, tumor, node, metastasis; PR, partial response; and —, no response noted.
Patient was assessed using the original TNM criteria, which did not account for blood involvement.